The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans… The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans…

RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?

For feedback or concerns regarding this content, please contact us at [email protected]

Secretary of Health and Human Services Robert F. Kennedy Jr.

The Associated Press

Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there.

Tylenol may be only the beginning.

For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us.

On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access.

Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.)

One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues.

Another frequent target of Kennedy’s are statins, which more than 92 million Americans take to prevent heart disease and lower cholesterol. Most studies find that statins are both safe and help to prevent serious heart disease, which is the number one killer of Americans.

Yet Children’s Health Defense, the organization Kennedy founded, has published articles questioning the relationship of cholesterol to heart disease, with one calling them “overprescribed and unnecessary.” And earlier this year, as HHS Secretary, Kennedy claimed on a podcast that pharmaceutical companies manipulated studies to show they work.

One of the rationales for the agency’s recent crackdown on pharmaceutical ads is increased uptake of the drugs. Statins were the drugs of an older generation. Also in the crosshairs are newer innovations, like the increasingly popular GLP-1s used to treat diabetes (Ozempic, Mounjaro) and obesity (Wegovy, Zepbound). These drugs have recently been approved for additional health problems, such as sleep apnea, and are even being investigated for drug addiction.

That remarkable success hasn’t stopped Kennedy from criticizing their cost (they are expensive) and making false claims about them. For example, he falsely said that Novo Nordisk, which makes Ozempic, doesn’t market it in Europe. (It does.) He’s also said that ensuring Americans eat a good diet would solve the obesity problem–but multiple clinical studies have shown that GLP-1s are vastly superior to diet alone to helping people not only lose weight but keep it off.

In a first jab at their use, Kennedy rejected a plan to have Medicare cover the cost of GLP-1 drugs for obesity, which would have given 7 million Americans access to them, in April. (Medicare already covers these treatments for diabetes.) Could more restrictions on their use be seen down the road?

“They’re counting on selling it to Americans because we’re so stupid and so addicted to drugs,” Kennedy told viewers of Fox News about Ozempic and its manufacturer Novo Nordisk.

It’s not clear what, if anything, would change his mind.

MORE FROM FORBES

ForbesTrump’s Unproven Claims About Tylenol And Autism Are Reaching Millions On TikTokForbesRFK Jr.’s CDC Is Poised To Restrict Vaccines Even FurtherForbesThis Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug Pricing

Source: https://www.forbes.com/sites/alexknapp/2025/09/26/rfk-jr-is-targeting-vaccines-and-tylenol-are-prozac-and-ozempic-next/

Market Opportunity
SynFutures Logo
SynFutures Price(F)
$0.005578
$0.005578$0.005578
-1.39%
USD
SynFutures (F) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Litecoin Fluctuates Below The $116 Threshold

Litecoin Fluctuates Below The $116 Threshold

The post Litecoin Fluctuates Below The $116 Threshold appeared on BitcoinEthereumNews.com. Sep 17, 2025 at 23:05 // Price Litecoin price analysis by Coinidol.com: LTC price has slipped below the moving average lines after hitting resistance at $120. Litecoin price long-term prediction: bearish The 21-day SMA support helped to alleviate the selling pressure. In other words, the price of the cryptocurrency is above the 21-day SMA support but below the 50-day SMA barrier. This suggests that Litecoin will be trapped in a narrow range for a few days. If the 21-day SMA support or the 50-day SMA barrier is overreached, the cryptocurrency will trend upwards. For example, if the LTC price breaks through the 50-day SMA barrier, it will rise to a high of $124. Litecoin will fall to its current support level of $106 if the 21-day SMA support is broken. Technical Indicators  Resistance Levels: $100, $120, $140 Support Levels: $60, $40, $20 LTC price indicators analysis Litecoin’s price is squeezed between the moving average lines. It is unclear in which direction Litecoin will move. The moving average lines are horizontal in both charts. However, the price bars are limited to the distance between the moving averages. The price bars on the 4-hour chart are below the moving average lines. LTC/USD price chart – September 17, 2025 What is the next move for LTC? On the 4-hour chart, Litecoin is currently trading in a bearish trend zone. The altcoin is trading above the $112 support and below the moving average lines, which represent resistance at $116. The upward movement is hindered by the moving average lines, which are causing the price to oscillate within a limited range. Meanwhile, the signal for the cryptocurrency is bearish, with price bars below the moving average…
Share
BitcoinEthereumNews2025/09/18 08:15
CME to launch Solana and XRP futures options on October 13, 2025

CME to launch Solana and XRP futures options on October 13, 2025

The post CME to launch Solana and XRP futures options on October 13, 2025 appeared on BitcoinEthereumNews.com. Key Takeaways CME Group will launch futures options for Solana (SOL) and XRP. The launch date is set for October 13, 2025. CME Group will launch futures options for Solana and XRP on October 13, 2025. The Chicago-based derivatives exchange will add the new crypto derivatives products to its existing digital asset offerings. The launch will provide institutional and retail traders with additional tools to hedge positions and speculate on price movements for both digital assets. The futures options will be based on CME’s existing Solana and XRP futures contracts. Trading will be conducted through CME Globex, the exchange’s electronic trading platform. Source: https://cryptobriefing.com/cme-solana-xrp-futures-options-launch-2025/
Share
BitcoinEthereumNews2025/09/18 01:07
US-Israel airstrikes trigger 700% surge in Iran crypto outflows

US-Israel airstrikes trigger 700% surge in Iran crypto outflows

The post US-Israel airstrikes trigger 700% surge in Iran crypto outflows appeared on BitcoinEthereumNews.com. Homepage > News > Business > US-Israel airstrikes
Share
BitcoinEthereumNews2026/03/05 16:01